Renormalized One-loop Theory of Correlations in Disordered Diblock Copolymers

A renormalized one-loop theory (ROL) is used to calculate corrections to the random phase approximation (RPA) for the structure factor \Sc(q) in disordered diblock copolymer melts. Predictions are given for the peak intensity $S(q^{\star})$, peak position $q^{\star}$, and single-chain statistics for symmetric and asymmetric copolymers as functions of $\chi N$, where $\chi$ is the Flory-Huggins interaction parameter and $N$ is the degree of polymerization. The ROL and Fredrickson-Helfand (FH) theories are found to yield asymptotically equivalent results for the dependence of the peak intensity $S(q^{\star})$ upon $\chi N$ for symmetric diblock copolymers in the limit of strong scattering, or large $\chi N$, but yield qualitatively different predictions for symmetric copolymers far from the ODT and for asymmetric copolymers. The ROL theory predicts a suppression of $S(q^\star)$ and a decrease of $q^{\star}$ for large values of $\chi N$, relative to the RPA predictions, but an enhancement of $S(q^{\star})$ and an increase in $q^{\star}$ for small $\chi N$ ($\chi N < 5$). By separating intra- and inter-molecular contributions to $S^{-1}(q)$, we show that the decrease in $q^{\star}$ near the ODT is caused by the $q$ dependence of the intermolecular direct correlation function, and is unrelated to any change in single-chain statistics, but that the increase in $q^{\star}$ at small values of $\chi N$ is a result of non-Gaussian single-chain statistics.Comment: 16 pages, 13 figures, submitted to J. Chem. Phy

Impact of lactoferrin on bone regenerative processes and its possible implementation in oral surgery - a systematic review of novel studies with metanalysis and metaregression

Background: Lactoferrin is an iron - binding glycoprotein with anti-inflammatory and anabolic properties found in many internal fluids. It is worth looking at novel studies, because of their methodology and observations that may once be applicable in modern implantology. The aim of the study is to answer the question if lactoferrin is a promising factor for bone regenerative process in oral surgery. Method: An electronic search was conducted on 14th October 2019 on the PubMed, Scopus and Web of Science databases. The keywords used in the search strategy were: lactoferrin AND bone regeneration AND oral surgery. The qualitative evaluation was conducted using the Jadad and Newcastle-Ottawa Quality Assessment Form. Then a metanalysis of a new bone growth and percentage of the resorbed graft were performed with the metaregression of lactoferrin dose to its outcome effects on bone regeneration. Results: The search strategy identified potential articles: 133 from PubMed, 2 from Scopus, 4 from Web of science. After removal of duplicates, 136 articles were analyzed. Subsequently, 131 papers were excluded because they did not meet the inclusion criteria. The remaining 5 papers were included in the qualitative synthesis. The use of lactoferrin clearly increases the growth of a newly formed bone (2.58, CI:[0.79, 4.37]), as well as shortens the time of the graft resorption (- 1.70, Cl:[3.43, 0.03]) and replaces it with a species-specific bone. Heterogeneity is significant at p &lt; 0.001 level. Metaregression indicates that one unit increase in the log (Treatment dose), i.e. a 2.78 times increase of the Treatment dose, results in an increase of the Effect size by 0.682. Conclusions: The use of lactoferrin both systemically and locally promotes anabolic processes (new bone formation). There is a relationship between the increase in administered dose of lactoferrin and the intensity of new bone formation. However, it is not only necessary to continue experimental research, but also to extend it to the clinical studies on patients, due to the limitations of different animal model research and different methodology, to introduce lactoferrin as a standard procedure for the treatment of bone defects, because it is a promising product

DNA Barcoding Identifies Unknown Females and Larvae of Fannia R.-D. (Diptera: Fanniidae) from Carrion Succession Experiment and Case Report.

Application of available keys to European Fanniidae did not facilitate unequivocal species identification for third instar larvae and females of Fannia Robineau-Desvoidy, 1830 collected during a study of arthropod succession on pig carrion. To link these samples to known species, we took the advantage of molecular identification methods and compared newly obtained cytochrome oxidase subunit I (COI) barcode sequences against sequences deposited in reference databases. As an outcome of the results obtained, we describe for the first time a third instar larva of Fannia nigra Malloch, 1910 and Fannia pallitibia (Rondani, 1866) and a female of Fannia collini d'Assis-Fonseca, 1966. We provide combinations of characters allowing for discrimination of described insects from other Fanniidae. We provide an update for the key by Rozkošný et al. 1997, which allows differentiation between females of F. collini and other species of Fanniidae. Additionally, we provide a case of a human cadaver discovered in Southern Poland and insect fauna associated with it as the first report of F. nigra larvae developing on a human body

Venture Capital and Business Angels and the Creation of Innovative Firms in Poland

The article also points out that conditions fostering further development of the described types of entrepreneurship and innovation financing and a dynamic environment generating innovative capacity should be created.W artykule zasygnalizowano również potrzebę kreowania uwarunkowań sprzyjających rozwojowi opisanych form finansowania przedsiębiorczości, innowacyjności i dynamicznego otoczenia generującego zdolności innowacyjne

2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs

This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1.alpha.,25-dihydroxyvitamin D.sub.3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity

2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses

This invention discloses 2.alpha.-methyl and 2.beta.-methyl analogs of 19,26-dinor-1.alpha.,25-dihydroxyvitamin D.sub.3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds have little, if any, in vivo calcemic activity and therefore may be used to treat autoimmune disorders in humans as well as secondary hyperparathyroidism and renal osteodystrophy